Global Outpatient Oncology Infusion Market - 2023-2030

Global Outpatient Oncology Infusion Market - 2023-2030

Global outpatient oncology infusion market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.

Outpatient oncology infusion is a crucial aspect of cancer treatment that involves administering chemotherapy, immunotherapy, targeted therapy and other supportive medications to patients outside a hospital setting. This approach has several benefits, including increased convenience, reduced healthcare costs, and the ability for individuals to receive essential cancer care while maintaining a relatively normal daily routine.

Outpatient oncology infusion centres have a highly specialized team of healthcare professionals that includes oncology nurses and pharmacists. These professionals closely monitor patients, manage potential side effects, and provide valuable support throughout the treatment process. These centres are specifically designed to create a comfortable and patient-focused environment, which helps alleviate some of the burdens associated with cancer treatment and improves the overall quality of life for patients undergoing cancer therapy.

Market Dynamics: Drivers and Restraints

Advancements in cancer infusion therapy are expected to drive the market growth

Outpatient oncology infusion therapy devices serve the purpose of safely and effectively delivering chemotherapy, immunotherapy, and other cancer treatments to patients. These devices are designed to be portable, allowing patients to receive treatment in the comfort of their homes, which reduces the need for hospital visits and improves outcomes. The advancements in these devices have made cancer treatment more accessible and convenient for patients.

The advancements in cancer infusion therapy have also led to the development of new drugs and therapies. For instance, on August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. Immunotherapy has also become an advanced treatment strategy among the different therapeutic options for various malignancies, including haematological cancers.

Therefore, advancements in cancer infusion therapy have made cancer treatment more accessible, convenient, and effective for patients. The development of new drugs and therapies has also improved patient outcomes, and has the potential to benefit people with cancer all over the world.

Restraint:

Reimbursement issues, regulatory and compliance challenges, lack of skilled professionals, and patient safety concerns are the factors expected to hamper the market over the forecast period.

For more details on this report – Request for Sample

Segment Analysis

The global outpatient oncology infusion market is segmented based on product, therapy, cancer type and region.

The infusion pumps from the product segment accounted for approximately 56.6% of the outpatient oncology infusion market share

Outpatient oncology infusion pumps are specialized medical devices designed for the controlled and continuous delivery of chemotherapy medications, targeted therapies, and supportive drugs to cancer patients in an ambulatory or home setting.

Their primary advantage is providing patients with greater comfort, flexibility, and the ability to receive treatment outside of a hospital or clinic, thereby improving their quality of life. These devices offer precise drug delivery, reducing the risk of side effects and complications, and can be programmed to match a patient's specific treatment regimen.

The market for outpatient oncology infusion pumps is driven by several factors, including the rising incidence of cancer, the increasing shift towards home-based care, the demand for cost-effective and patient-centric treatment options, and technological advancements in these devices.

For instance, according to the American Cancer Society, in 2022, there were an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.

Furthermore, several leading companies in the healthcare industry manufacture oncology infusion pumps, including Medtronic, Becton, Dickinson and Company, and B. Braun Melsungen among others, contributing to the growth and innovation in this market.

Geographical Analysis

North America accounted for approximately 41.3% of the market share in 2022

North America is expected to hold the largest market share, owing to the increasing prevalence of cancer, a growing partnership among market players, growing FDA clearance of products and the presence of key players.

For instance, on February 28, 2022, American Oncology Network, LLC (AON) is a fast-growing medical oncology provider that focuses on supporting the long-term viability of cancer treatment in community-based settings. AON agreed with InfuSystem Holdings, Inc., a leading national healthcare service provider that facilitates outpatient care for durable medical equipment manufacturers and healthcare providers.

Effective January 1, 2022, InfuSystem will provide ambulatory infusion pumps and services to AON. The agreement includes electronic infusion pumps for continuous chemotherapy treatment, a 24/7 clinical hotline, biomedical services, accompanying supplies, and revenue cycle management.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the outpatient oncology infusion market. During the pandemic, healthcare providers and patients opted for home-based care to reduce the risk of exposure to the virus.

Outpatient oncology infusion pumps gained popularity as they allowed cancer patients to continue their treatments safely outside of the hospital. This promoted social distancing and reduced the risk of infection.

Telehealth services also saw a rapid expansion in response to the pandemic, complementing the use of outpatient infusion pumps. With telehealth consultations, healthcare professionals could monitor patients remotely and make necessary adjustments to their treatment plans, further enhancing the convenience and safety of outpatient care.

Regulatory authorities facilitated quicker market access and innovation in the sector by expediting the approval processes for certain medical devices, including outpatient infusion pumps, in response to the urgent need for remote healthcare solutions during the pandemic.

However, the global disruption of supply chains caused by lockdowns and restrictions has hindered the production and distribution of medical devices, including oncology infusion pumps. As a result, patients have experienced delays and shortages in accessing these critical devices. Hospitals and healthcare facilities have faced significant financial strain due to the suspension of elective procedures and a decrease in patient visits. This financial pressure has potentially limited investments in outpatient oncology infusion services.

Additionally, some cancer patients have become hesitant to continue their outpatient treatment due to the fear of exposure to COVID-19 in healthcare settings, despite the benefits of oncology infusion pumps.

Therefore, the COVID-19 pandemic has led to an increase in the use of outpatient oncology infusion pumps. This was due to the emphasis on home-based care and telehealth. However, the pandemic also brought challenges such as disruptions in the supply chain, reduced healthcare facility revenues, and heightened patient anxiety. As a result, the overall impact on the market was a complex interplay of these positive and negative factors.

Market Segmentation:

By Product
• Infusion Pumps
• Intravenous Sets
• Needleless Connectors
• IV Cannulas

By Therapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Hormone Therapy
• Others

By Cancer Type
• Solid Tumors
Breast
Lung
Prostate
Colon Cancer
Others
• Hematologic Malignancies
Leukemia
Lymphoma
Multiple Myeloma
Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the outpatient oncology infusion market include InfuSystem, Intera Oncology, Intuvie, LLC, Baxter, Delta Med, Becton, Dickinson and Company, ICU Medical, Micrel Medical Devices SA, Viltechmeda, and B. Braun SE among others.

Key Development
• On March 26, 2022, Shanghai MicroPort Lifesciences Co., Ltd. (MicroPort Lifesciences) received marketing approval from China’s National Medical Products Administration (NMPA) for its independently developed new AutoEx Chemotherapy Infusion Pump (AutoEx).
• On February 28, 2022, American Oncology Network, LLC (AON) is a fast-growing medical oncology provider that focuses on ensuring the long-term sustainability of cancer treatment in community-based settings. AON agreed with InfuSystem Holdings, Inc., a leading national healthcare service provider. The deal, which takes effect on January 1, 2022, will enable InfuSystem to provide ambulatory infusion pumps and services to AON, to facilitate outpatient care for durable medical equipment manufacturers and healthcare providers.

Why Purchase the Report?
• To visualize the global outpatient oncology infusion segmentation based on product, therapy, cancer type and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of outpatient oncology infusion market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global outpatient oncology infusion market report would provide approximately 61 tables, 60 figures, and 189 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies